Pilot Trial Studying the Effects of Pioglitazone in Comparison to Placebo on Myocardial Function and Oxidative Stress in Patients With Type II Diabetes and Insulin Resistance Undergoing Elective PTCA. A Randomized Double-Blinded Phase II Study.
Phase of Trial: Phase II
Latest Information Update: 11 Aug 2013
At a glance
- Drugs Pioglitazone (Primary)
- Indications Coronary artery disease; Type 2 diabetes mellitus
- Focus Biomarker; Pharmacodynamics
- Sponsors Takeda Pharma
- 10 Jun 2017 Biomarkers information updated
- 12 Jul 2011 New source identified and integrated (European Clinical Trials Database)
- 23 Jan 2009 Planned end date changed from 1 Dec 2008 to 1 Feb 2009 as reported by ClinicalTrials.gov.